Document is current
Any future updates will be listed below
-
Authors
Barnes, Alex
Toson, Barbara
Bryant, R. V.
Mukherjee, Sutapa
Andrews, Jane M.
Spizzo, Paul
Mountifield, Réme
- License Information
-
More Information
Article History
Received: 15 November 2023
Accepted: 24 April 2024
First Online: 30 April 2024
Declarations
:
: Ethics approval for this study was obtained from the Southern Adelaide Human Research Ethics Committee (203.20) and informed consent was obtained from all participants.
: Not applicable.
: Jane M Andrews: Speakers fees, and Ad Boards from: Abbott, AbbVie, Allergan, Anatara, AstraZeneca, Bayer, BMS 2020, Celegene, Celltrion, Falk, Ferring, Gilead, Hospira, Im-muninc, ImmunsanT, Janssen, MSD, Nestle, Novartis, Progen-ity, Pfizer, Sandoz, Shire, Takeda, Vifor, RAH research Fund, The Hospital Research Fund 2020-2022, The Helmsley Trust 2020-2023. Reme Mountifield: Speakers fees, and Ad Boards from: Abbott, AbbVie, Allergan, Anatara, AstraZeneca, Bayer, BMS 2020, Celegene, Celltrion, Falk, Ferring, Gilead, Hospira, Im-muninc, ImmunsanT, Janssen, MSD, Nestle, Novartis, Progen-ity, Pfizer, Sandoz, Shire, Takeda. Rob V Bryant: has received Grant/Research support/Speaker fees (all paid to employer for research support): AbbVie, Ferring, Janssen, Shire, Takeda, Emerge Health; shareholder in BiomebankNo conflict of interest: Alex Barnes, Sutapa Mukherjee, Paul Spizzo, Barbara Toson.
